clonidine has been researched along with Exfoliation Syndrome in 3 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
Exfoliation Syndrome: The deposition of flaky, translucent fibrillar material most conspicuous on the anterior lens capsule and pupillary margin but also in both surfaces of the iris, the zonules, trabecular meshwork, ciliary body, corneal endothelium, and orbital blood vessels. It sometimes forms a membrane on the anterior iris surface. Exfoliation refers to the shedding of pigment by the iris. (Newell, Ophthalmology, 7th ed, p380)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Following the addition of apraclonidine the mean, peak and range of IOP were statistically similar between groups and only the standard deviations remained higher in the exfoliation glaucoma group (p < 0." | 5.09 | The comparative ocular hypotensive effect of apraclonidine with timolol maleate in exfoliation versus primary open-angle glaucoma patients. ( Konstas, AG; Maltezos, A; Mantziris, DA; Sine, CS; Stewart, WC, 1999) |
| "Clonidine did not cause allergic reaction in patients with proven allergy to apraclonidine, indicating that there is no cross-reactivity with apraclonidine." | 1.31 | Clonidine provides an allergy-free alternative in glaucoma patients with proven allergy to apraclonidine. ( Geyer, O; Lazar, M; Neudorfer, M; Pianka, P; Schmidt, KG, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kotecha, A | 1 |
| Elsheikh, A | 1 |
| Roberts, CR | 1 |
| Zhu, H | 1 |
| Garway-Heath, DF | 1 |
| Konstas, AG | 1 |
| Maltezos, A | 1 |
| Mantziris, DA | 1 |
| Sine, CS | 1 |
| Stewart, WC | 1 |
| Geyer, O | 1 |
| Schmidt, KG | 1 |
| Pianka, P | 1 |
| Neudorfer, M | 1 |
| Lazar, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Central Corneal Thickness and 24-hour Fluctuation of Intraocular Pressure[NCT00941525] | Phase 4 | 174 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for clonidine and Exfoliation Syndrome
| Article | Year |
|---|---|
The comparative ocular hypotensive effect of apraclonidine with timolol maleate in exfoliation versus primary open-angle glaucoma patients.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Aged; Circadian Rhythm; Clonidine; Drug Ther | 1999 |
2 other studies available for clonidine and Exfoliation Syndrome
| Article | Year |
|---|---|
Corneal thickness- and age-related biomechanical properties of the cornea measured with the ocular response analyzer.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Aging; Biomechanical Phenomena; Clonidine | 2006 |
Clonidine provides an allergy-free alternative in glaucoma patients with proven allergy to apraclonidine.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Clonidine; Conjunctivitis, Al | 2000 |